KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Other financing activities (2020 - 2023)

Historic Other financing activities for GoodRx Holdings (GDRX) over the last 4 years, with Q1 2023 value amounting to $3.7 million.

  • GoodRx Holdings' Other financing activities fell 6119.65% to $3.7 million in Q1 2023 from the same period last year, while for Dec 2024 it was -$13.8 million, marking a year-over-year decrease of 3090.38%. This contributed to the annual value of $2.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that GoodRx Holdings reported Other financing activities of $3.7 million as of Q1 2023, which was down 6119.65% from -$17.6 million recorded in Q4 2022.
  • GoodRx Holdings' 5-year Other financing activities high stood at $81.7 million for Q4 2020, and its period low was -$17.6 million during Q4 2022.
  • In the last 4 years, GoodRx Holdings' Other financing activities had a median value of $9.6 million in 2022 and averaged $17.2 million.
  • In the last 5 years, GoodRx Holdings' Other financing activities soared by 49362.08% in 2021 and then tumbled by 13029.42% in 2022.
  • Over the past 4 years, GoodRx Holdings' Other financing activities (Quarter) stood at $81.7 million in 2020, then decreased by 29.09% to $58.0 million in 2021, then plummeted by 130.29% to -$17.6 million in 2022, then surged by 121.13% to $3.7 million in 2023.
  • Its Other financing activities was $3.7 million in Q1 2023, compared to -$17.6 million in Q4 2022 and $3.3 million in Q3 2022.